NEW YORK (GenomeWeb News) - Third Wave Technologies said today that it has completed patient enrollment for a clinical trial involving its two human papillomavirus tests.
 
The company said it has enrolled 2,000 normal subjects and 1,400 women with atypical Pap test results. Next steps in the clinical trial include obtaining final colposcopy and biopsy data, validating and opening a database, and submitting pre-market approval applications to the US Food and Drug Administration.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Though many details have yet to be worked out, the draft deal for the UK's withdrawal from the EU is giving researchers some hints for what they can expect, Nature News says.

DNA testing has solved a 100-year-old mystery contained in the skull and teeth samples of a now-extinct monkey that once inhabited Jamaica, Gizmodo reports.

As the UN ponders a ban on gene drives, one malaria researcher says there are less dramatic ways to fight the disease in Africa than unleashing GM mosquitoes on a whole continent.

In Nature this week: an improved reference genome of the Aedes aegypti mosquito, genomes of four species of truffles, and more.